NKMAX stakeholders approve NKGen Biotech's acquisition; closing expected early August 2025

NKGen Biotech, Inc.

NKMAX stakeholders approved the Conditional Investment Agreement for NKGen's M&A of NKMAX; all previously disclosed conditions satisfied.
Acquisition expected to close in early August 2025; NKMAX is a >10% shareholder of NKGen Biotech.
NKMAX is a clinical-stage biotech (immune cell therapies, bioreagents, diagnostics) based in Seoul, listed on KOSDAQ (trading suspended).
NKGen was selected as final preferred bidder in January 2025; Seoul Bankruptcy Court approved the agreement in December 2024.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.